• S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

  • 2023/11/15
  • 再生時間： 32 分
  • ポッドキャスト

S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

    Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
続きを読む 一部表示

S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinibに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。